Bioanalysis Zone

Challenges in antibody–drug conjugate discovery: a bioconjugation and analytical perspective


“…the mode of attachment of the payload linker to the antibody must have a perfect fit for its success.”

With the approval of Adcetris to treat Hodgkin’s lymphoma and Kadcyla to treat Her2 positive advanced breast cancer, antibody–drug conjugates (ADCs) are fast becoming a well-proven strategy to treat cancer. For successful development of ADCs, several parameters at early stages in research need careful examination.

To view restricted content, please:

Leave A Comment

Please wait...

Bioanalysis Zone New Investigator Award

Why not start this year by doing something good by nominating an early career scientist for the Bioanalysis Zone New Investigator Award. Complete the details below to register your interest!